Eso Pediatric Obesity Pharmacotherapy Admin

---
name: eso-pediatric-obesity-pharmacotherapy-admin
description: Determines when to administer FDA-approved obesity pharmacotherapy in pediatric patients, requiring a concomitant lifestyle modification program of the highest intensity and prescribing only by experienced clinicians. Triggers include documented failure of intensive lifestyle modification to limit weight gain or ameliorate comorbidities in patients with obesity (BMI ≥95th percentile).
---

# Determine requirements for administering obesity pharmacotherapy

## STEP 1 — Gather Information
Collect patient age, sex, BMI percentile, weight status (overweight vs obesity), history of lifestyle modification attempts (duration, intensity, components), presence of obesity‑related comorbidities, clinician’s experience with anti‑obesity agents, and availability of a high‑intensity lifestyle modification program.

## STEP 2 — Rule In / Rule Out
Rule in if the patient has obesity (BMI ≥95th percentile) and has failed a formal intensive lifestyle modification program to limit weight gain or ameliorate comorbidities; rule out if the patient is overweight only (BMI 85th–94th percentile), aged <12 years (except in clinical trials), lacks access to a high‑intensity lifestyle program, or the prescribing clinician lacks experience with anti‑obesity agents.

## STEP 3 — Classify or Stratify
Stratify by age group (12–15 years vs ≥16 years) to align with FDA‑approved agent labeling and by comorbidity burden (none, moderate, extreme) to guide medication selection and monitoring intensity.

## STEP 4 — Decide
If ruled in, prescribe FDA‑approved pharmacotherapy only when combined with the concomitant highest‑intensity lifestyle modification program and under supervision of an experienced clinician; schedule monthly follow‑up for weight, adverse effects, and adherence; if <4% BMI/BMI z‑score reduction after 12 weeks at full dose, discontinue medication and reevaluate.

## Clinical Guardrails / Mimics / Pitfalls
Do not initiate pharmacotherapy without a concurrent high‑intensity lifestyle program; avoid prescribing by clinicians lacking experience with anti‑obesity agents; do not use medication in overweight‑only patients; monitor for GI side effects (e.g., with orlistat) and vitamin deficiencies; discontinue if insufficient weight loss or adverse reactions outweigh benefit; never substitute pharmacotherapy for lifestyle modification.

## Concrete Clinical Example
A 14‑year‑old girl with BMI at the 98th percentile completes a 6‑month, multidisciplinary, high‑intensity lifestyle program (diet, activity, behavior) without meaningful weight loss or improvement in hypertension; her pediatric endocrinologist, experienced in orlistat use, prescribes orlistat 120 mg TID with meals while continuing the lifestyle program; after 12 weeks she shows a 0.8 kg/m² BMI reduction and tolerates the medication, so therapy is continued.

**Source:** Pediatric Obesity Assessment, Treatment, and Prevention: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2017, DOI:10.1210/jc.2016-2573